ITM‘s Clinical Trials for GEP-NET Patients
Neuroendocrine tumors are a rare form of cancer and are frequently of gastroenteropancreatic origin (GEP-NETs). GEP-NETs are often asymptomatic and diagnosed at a late stage with metastases and with limited possibility of surgical removal, thus with a still high unmet medical need for treatment.
COMPETE and COMPOSE are two phase III clinical trials to evaluate targeted radiopharmaceutical therapy (RPT) with n.c.a. Lutetium 177 edotreotide in patients with neuroendocrine tumors of gastroenteric or pancreatic origin (GEP-NETs).
Information for patients
Are you interested in learning more about neuroendocrine tumors, or clinical trials investigating RPT for GEP-NETs? Access more information, including participating clinical centers, under the following link.
Information for healthcare professionals
Please find more information on the clinical trials and /or patient enrollment under the following link.